AMZN
Amazon.com, Inc.
AMZN has the edge over KEQU overall, supported by stronger valuation and stronger modeled upside.
KEQU
Kewaunee Scientific Corporation
KEQU trails on the overall score without a compensating advantage in the available component scores.
AMZN Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Healthy | |
| Weak | |
| Healthy |
AMZN's revenue, profitability and balance sheet are currently healthy, but its cash flow is weak.
KEQU Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Under pressure | |
| Strong |
KEQU's balance sheet is currently strong, and its revenue and profitability are stable, but its cash flow is under pressure.
AMZN PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 22x | $267 | — |
| Forward | 27x | $267 | — |
| Cheap | 34x | $415 | +55% |
| Fair | 60x | $745 | +179% |
| Expensive | 102x | $1,262 | +372% |
Historical ranges are pointers, not guarantees.
AMZN has the edge over KEQU in the historical PE scenario, which offers more potential upside but is not a forecast.
KEQU PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 7.5x | $20.79 | -42% |
| Fair | 11x | $29.03 | -19% |
| Expensive | 13x | $36.49 | +1.5% |
| Current | 13x | $35.94 | — |
Historical ranges are pointers, not guarantees.
KEQU's PE is in its expensive range at 13x.
AMZN Forward outlook
| Metric | Outlook |
|---|---|
| Strongly deteriorating | |
| Strong growth | |
| Growth | |
| Improving | |
| Moderate | |
| Moderate |
Analysts expect earnings and revenue growth for AMZN, with profitability improving.
KEQU Forward outlook
There aren't enough analyst estimates for KEQU to show an outlook.
AMZN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $9.87 | -20% |
| Q3 2026 | $12.37 | +75% |
| Q2 2026 | $12.43 | +89% |
| Q1 2026 | $8.36 | +36% |
| Q4 2025 | $7.17 | +30% |
| Q3 2025 | $7.08 | +52% |
| Q2 2025 | $6.56 | +57% |
| Q1 2025 | $6.14 | +72% |
| Q4 2024 | $5.53 | +91% |
AMZN has the edge over KEQU on earnings, with more consistent year-over-year improvement.
KEQU Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | $2.76 | -33% |
| Q2 2026 | $3.22 | -16% |
| Q1 2026 | $3.72 | -37% |
| Q4 2025 | $3.94 | -38% |
| Q3 2025 | $4.13 | -34% |
| Q2 2025 | $3.83 | -40% |
| Q1 2025 | $5.94 | +98% |
| Q4 2024 | $6.34 | +164% |
KEQU's earnings per share have fallen from their peak: $2.76 over the past year, against $6.38 in early 2024.
AMZN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $201.9B | +12% |
| Q2 2026 | $200.6B | +20% |
| Q1 2026 | $181.5B | +17% |
| Q4 2025 | $213.4B | +14% |
| Q3 2025 | $180.2B | +13% |
| Q2 2025 | $167.7B | +13% |
| Q1 2025 | $155.7B | +8.6% |
| Q4 2024 | $187.8B | +10% |
AMZN's revenue has grown year over year every quarter since late 2020: $202B last quarter, up 12% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 14% | +4.2 points |
| Q2 2026 | 14% | +2.3 points |
| Q1 2026 | 13% | +1.3 points |
| Q4 2025 | 12% | +0.4 points |
| Q3 2025 | 9.7% | -1.3 points |
| Q2 2025 | 11% | +1.5 points |
| Q1 2025 | 12% | +1.1 points |
| Q4 2024 | 11% | +3.5 points |
AMZN has the edge over KEQU on profitability, with a higher operating margin.
KEQU Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $66.3M | -6.7% |
| Q2 2026 | $71.4M | -7.5% |
| Q1 2026 | $69.4M | +3.3% |
| Q4 2025 | $70.1M | +47% |
| Q3 2025 | $71.1M | +47% |
| Q2 2025 | $77.1M | +36% |
| Q1 2025 | $67.2M | +44% |
| Q4 2024 | $47.8M | -5.3% |
KEQU's revenue is growing: $66M last quarter, down 6.7% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 4.8% | -2 points |
| Q2 2026 | 7.3% | -3.7 points |
| Q1 2026 | 3.7% | +0.4 points |
| Q4 2025 | 5.9% | -3.4 points |
| Q3 2025 | 6.8% | +1.4 points |
| Q2 2025 | 11% | +1.2 points |
| Q1 2025 | 3.4% | -4.8 points |
| Q4 2024 | 9.3% | -0.9 points |
KEQU's operating margin was 4.8% last quarter, down 2 points from the same quarter a year ago.
AMZN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$34.8B | -8202% |
| Q2 2026 | -$8.8B | -2757% |
| Q1 2026 | -$18.2B | -$10.2B |
| Q4 2025 | $14.9B | -16% |
| Q3 2025 | $430M | -87% |
| Q2 2025 | $332M | -96% |
| Q1 2025 | -$8B | -297% |
| Q4 2024 | $17.8B | -36% |
AMZN's free cash flow was −$46.9B over the past year, against $10.6B the year before.
KEQU Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $1.2M | -76% |
| Q2 2026 | $4.5M | -49% |
| Q1 2026 | $11M | +$13.9M |
| Q4 2025 | -$5.8M | -175% |
| Q3 2025 | $5M | +$6.1M |
| Q2 2025 | $8.9M | +5256% |
| Q1 2025 | -$3M | -133% |
| Q4 2024 | $7.8M | +$8.3M |
KEQU has the edge over AMZN on cash generation, producing positive trailing cash flow while its opponent burns cash.
AMZN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.2% | +26M shares |
| 1 year | +0.8% | +84M shares |
| 3 years | +3.5% | +371M shares |
| 5 years | +6.1% | +629M shares |
| Available history | +8.2% | +829M shares |
AMZN has 10.9B diluted shares, up 0.8% from a year ago.
| Quarter | Spent |
|---|---|
| Q1 2024 | — |
| Q4 2023 | — |
| Q3 2023 | — |
| Q2 2023 | — |
| Q1 2023 | — |
| Q4 2022 | — |
| Q3 2022 | — |
| Q2 2022 | $3.3B |
KEQU Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -2.1% | -62K shares |
| 1 year | -1.4% | -42K shares |
| 3 years | +1.2% | +36K shares |
| 5 years | +5.2% | +144K shares |
| Available history | +6.2% | +171K shares |
KEQU has the edge over AMZN on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $529,000 |
| Q2 2025 | $1.6M |
| Q2 2024 | $1.2M |
AMZN Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.7x | Very low |
| Q2 2026 | 0.3x | Very low |
| Q1 2026 | 0.1x | Very low |
| Q4 2025 | -0.1x | Net Cash |
| Q3 2025 | -0.1x | Net Cash |
| Q2 2025 | -0.0x | Net Cash |
| Q1 2025 | -0.1x | Net Cash |
| Q4 2024 | -0.2x | Net Cash |
AMZN's net debt is less than a year of its operating earnings (EBITDA), after holding more cash than debt a year ago.
KEQU Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.5x | Very low |
| Q2 2026 | 0.4x | Very low |
| Q1 2026 | 0.5x | Very low |
| Q4 2025 | 0.9x | Very low |
| Q3 2025 | 0.7x | Very low |
| Q2 2025 | 1.1x | Healthy |
| Q1 2025 | 1.5x | Healthy |
| Q4 2024 | -1.3x | Net Cash |
KEQU has the edge over AMZN on leverage, with a lower net debt burden relative to earnings.
AMZN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 57.1 | Neutral |
| Stochastic | 50.0 | Neutral |
AMZN's weekly RSI is 57 (neutral) and its Stochastic is 50 (neutral).
KEQU Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 50.8 | Neutral |
| Stochastic | 35.7 | Neutral |
KEQU's weekly RSI is 51 (neutral) and its Stochastic is 36 (neutral).
AMZN PE vs Consumer Cyclical Sector
| Metric | AMZN | Sector median | Relative |
|---|---|---|---|
| PE | 22x | 18x | 20% above |
| PE % | 4 | 47 | 43 pts below |
AMZN is trading at 22x earnings, a 20% premium to the Consumer Cyclical sector's median of 18x, though its recent earnings include one-off gains.
KEQU PE vs Consumer Cyclical Sector
| Metric | KEQU | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 18x | 28% below |
| PE % | 81 | 47 | 34 pts above |
KEQU has the edge over AMZN on valuation relative to its sector.
AMZN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $253.6 | 5.5% above |
| 20 week MA | $254.9 | 4.9% above |
| 50 week MA | $242.5 | 10% above |
| 100 week MA | $229.6 | 17% above |
| 200 week MA | $191.4 | 40% above |
AMZN has the edge over KEQU on trend strength, trading above more of its moving averages.
KEQU Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $33.9 | 6% above |
| 20 week MA | $35.4 | 1.5% above |
| 50 week MA | $37.0 | 2.9% below |
| 100 week MA | $42.5 | 15% below |
| 200 week MA | $35.1 | 2.4% above |
KEQU's trend is mixed: it's above three of its five weekly moving averages, and 2.4% above its 200-week average.
AMZN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $93.5 | $158.6 | +70% |
| 2021 | $158.6 | $171.1 | +7.8% |
| 2022 | $171.1 | $85.3 | -50% |
| 2023 | $85.3 | $151.9 | +78% |
| 2024 | $151.9 | $223.8 | +47% |
| 2025 | $223.8 | $232.5 | +3.9% |
| 2026 YTD | $232.5 | $267.4 | +15% |
AMZN has the edge over KEQU on returns for 2026, with the stronger performance.
KEQU Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $13.1 | $10.6 | -19% |
| 2021 | $10.6 | $12.3 | +16% |
| 2022 | $12.3 | $15.8 | +28% |
| 2023 | $15.8 | $29.1 | +85% |
| 2024 | $29.1 | $63.8 | +120% |
| 2025 | $63.8 | $38.0 | -40% |
| 2026 YTD | $38.0 | $35.9 | -5.4% |
KEQU's yearly returns have swung widely, from +120% in 2024 to −40% in 2025. It's down 5.4% so far in 2026.